Hinterberger W, Adler V, Bauer K, Haberhauer G, Habertheuer K H, Höniger S, Huber K, Kier P, Kittel E, Ruckser R
Ludwig-Boltzmann-Institut für Stammzelltransplantation, Wien.
Wien Med Wochenschr. 1995;145(2-3):34-40.
Autologous Transplantation of hematopoietic tissue with frozen hematopoietic stem cells is increasingly used for leukemias and lymphomas, but also for some solid tumors. In the past, autotransplants have been performed with bone marrow as the source of hematopoietic stem cells. Circulating, blood derived hematopoietic stem cells, however, allow safe engraftment of all cell lines after supralethal chemo-radiotherapy. This survey describes the role of autologous stem cell transplantation in disorders that are currently in the center of clinical and scientific interest. This estimation is based on the proportion of protocols dealing with, and centering on, autologous stem cell transplantation in the context of treatment for leukemias and solid tumors ("Oncodisc", "PDQ").
采用冷冻造血干细胞进行造血组织自体移植越来越多地用于白血病和淋巴瘤,也用于一些实体瘤。过去,自体移植是以骨髓作为造血干细胞的来源。然而,循环的、源自血液的造血干细胞能在超致死剂量放化疗后实现所有细胞系的安全植入。本综述描述了自体干细胞移植在目前临床和科研关注焦点疾病中的作用。这一评估基于在白血病和实体瘤治疗背景下涉及并以自体干细胞移植为核心的方案比例(“肿瘤光盘”,“医师数据查询”)。